Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.

Infection and immunity - 1 Feb 2015

Yang Zhiyong, Ramsey Jeremy, Hamza Therwa, Zhang Yongrong, Li Shan, Yfantis Harris G, Lee Dong, Hernandez Lorraine D, Seghezzi Wolfgang, Furneisen Jamie M, Davis Nicole M, Therien Alex G, Feng Hanping

Abstract excerpt

Clostridium difficile infection (CDI) represents the most prevalent cause of antibiotic-associated gastrointestinal infections in health care facilities in the developed world. Disease symptoms are caused by the two homologous exotoxins, TcdA and TcdB. Standard therapy for CDI involves administra...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bacterial
Share to Antibodies, Neutralizing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bacterial Toxins

Share to Clostridioides difficile

Share to Enterocolitis, Pseudomembranous

Share to Enterotoxins

Share to Receptors, IgG

Share to Vero Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 25486992
DOI: 10.1128/IAI.02897-14
PMCID: PMC4294251

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25486992-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.PMID 25486992Read ↗

Broad Coverage of Genetically Diverse Strains of Clostridium difficile by Actoxumab and Bezlotoxumab Predicted by <i>In Vitro</i> Neutralization and Epitope ModelingSemantic proximity Read ↗

An Update on Clostridioides difficile Binary ToxinSemantic proximity Read ↗

<i>Clostridioides difficile</i> toxin A and toxin B inhibit toxin-specific adaptive immune responses through glucosyltransferase-dependent activitySemantic proximity Read ↗

Selection of Nanobodies that Block the Enzymatic and Cytotoxic Activities of the Binary Clostridium Difficile Toxin CDTSemantic proximity Read ↗

Binary toxin expression by <i>Clostridioides difficile</i> is associated with worse diseaseSemantic proximity Read ↗

Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivoSemantic proximity Read ↗

Isofagomine inhibits multiple TcdB variants and protects mice from <i>Clostridioides difficile</i> induced mortalitySemantic proximity Read ↗

IL-33 protects from recurrent <i>C. difficile</i> infection by restoration of humoral immunitySemantic proximity Read ↗

Glucosyltransferase-dependent and independent effects of <i>Clostridioides difficile</i> toxins during infectionSemantic proximity Read ↗

Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin BSemantic proximity Read ↗

An Optimized, Synthetic DNA Vaccine Encoding the Toxin A and Toxin B Receptor Binding Domains of Clostridium difficile Induces Protective Antibody Responses In VivoSemantic proximity Read ↗

Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficileSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.